Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Mar 17, 2023
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Tax Payment
Common Stock
2023-03-15$30.65/sh−2,967$90,939→ 120,967 total
Footnotes (1)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the"RSA") for 7,540 shares. The RSA vests in three equal annual installments from March 15, 2021.